|
|  |  | | News and Views |  |  | Nature Biotechnology
22, 521 - 522 (2004)
doi:10.1038/nbt0504-521
Next-generation protein drugsIan M Tomlinson
Ian M. Tomlinson is Chief Scientific Officer of Domantis Limited, 315 Cambridge Science Park, Cambridge CB4 0WG, UK. ian.tomlinson@domantis.com
Ankyrin repeats generate high-affinity protein binders with biophysical properties that may favor therapeutic applications.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
|  | |